The reiteration of the 'Market Perform' rating and maintenance of the price target suggests that BMO Capital's view on CytomX Therapeutics remains unchanged. This stability in analyst outlook is likely to have a neutral short-term impact on CTMX's stock price, as it does not introduce new positive or negative information to the market.